Drugs / linzagolix
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03961932 | May 2019 → Jan 2020 | impaired renal function disease | ObsEva SA | Completed | No outcome recorded |
| Phase 1 | NCT03962049 | May → Oct 2019 | — | ObsEva SA | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02778399 | Jul 2016 → Apr 2018 | endometriosis | ObsEva SA | Completed | Met primary |
| Phase 36 trials · 2 met primary | ||||||
| Phase 3 | NCT04372121 | Mar 2020 → Jan 2021 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04335591 | Mar 2020 → Sep 2022 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03992846 | Jun 2019 → Oct 2021 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | Mixed |
| Phase 3 | NCT03986944 | May 2019 → Jan 2021 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03070951 | May 2017 → Sep 2019 | uterine corpus leiomyoma | ObsEva SA | Completed | Met primary |
| Phase 3 | NCT03070899 | Apr 2017 → Apr 2020 | leiomyoma | ObsEva SA | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT07732348 | Sep → Dec 2026 expected | female infertility, ovarian disorder | Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Linzagolix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07732348 ↗ |
| Known as | OBE2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03070899 ↗ |
| Action | Inhibit | “new investigational oral gonadotropin-releasing hormone antagonist” PMID 32505383 ↗ Jun 2020 |
| Route | Oral | “OBE2109 tablets for oral administration once daily” NCT02778399 ↗ |